Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Cytokinetics, Incorporated will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM Pacific Time [1] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [3] - The company’s product MYQORZO™ (aficamten) is approved for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) by the U.S. FDA and the China National Medical Products Administration [3] - The European Medicines Agency has adopted a positive opinion for MYQORZO™ (aficamten), with a decision from the European Commission expected in Q1 2026 [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction, alongside ongoing pre-clinical research in muscle biology [3]